Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions

(2015) A. Filatenkov et al.   CLINICAL CANCER RESEARCH

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

PD-1 Restrains Radiotherapy-Induced Abscopal Effect

(2015) S. S. Park et al.   Cancer Immunology Research

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

(2015) Sofia R. Gameiro et al.   Oncotarget

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

(2009) Y. Lee et al.   BLOOD

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody

(2009) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH